Eli Lilly and Co.’s Synjardy XR, or empagliflozin and metformin hydrochloride extended-release, has been approved by the FDA as a treatment for type 2 diabetes. The drug can help improve blood glucose control among type 2 diabetes patients when used with exercise and diet, but it is not indicated for those with type 1 diabetes or diabetic ketoacidosis, Eli Lilly said.